TNFRSF18 and neoplasm: Preclinical in vivo studies have shown that the anti-tumor activity of GITR agonist Abs is largely dependent on this mechanism of Treg depletion [36], although functional Treg modulation can also contribute to the anti-tumor immune responses [37].